{
    "clinical_study": {
        "@rank": "104349", 
        "arm_group": {
            "arm_group_label": "Stelara (ustekinumab) exposed", 
            "description": "Stelara (ustekinumab)-exposed pregnant women"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the OTIS Autoimmune Diseases in Pregnancy Study is to monitor planned and\n      unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic\n      effect of these medications and to follow live born infants for one year after birth. With\n      respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may be\n      relevant to a medication exposure during pregnancy, and these include both easily\n      recognizable defects which are visible at birth, as well as more subtle or delayed defects\n      that may not be readily identifiable without special expertise and observation beyond the\n      newborn period."
        }, 
        "brief_title": "Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project", 
        "completion_date": {
            "#text": "July 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Psoriasis", 
            "Pregnancy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Autoimmune Diseases", 
                "Psoriasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy\n      Project is to follow pregnant women or women who have delivered a baby, who have been\n      treated with Stelara within 3 months of their last menstrual period (LMP) or during\n      pregnancy to evaluate the possible effect of this medication on the pregnancy outcome\n      including child development and growth up to one year of age."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documentation of an exposure to Stelara (ustekinumab) during pregnancy or within 3\n             months prior to the first day of the last menstrual period (LMP) for any number of\n             days, at any time, at any dose, and at any time until completion of pregnancy.\n\n          -  Documentation of gestational timing of the exposure to Stelara (ustekinumab)\n\n        Exclusion Criteria:\n\n          -  Women who have not have an exposure to Stelara (ustekinumab) during pregnancy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Women who have had exposure to Stelara (ustekinumab) within 3 months of the last menstrual\n        period, or anytime during pregnancy, and who reside in the U.S. or Canada."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103361", 
            "org_study_id": "CNTO1275PSO4037"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "autoimmune disease", 
            "pregnancy", 
            "psoriasis", 
            "Stelara", 
            "ustekinumab", 
            "birth outcome", 
            "malformation", 
            "birth defect"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "link": {
            "description": "Official research website of the Organization of Teratology Information Specialists, Studies coordinated at the University of California, San Diego", 
            "url": "http://www.pregnancystudies.org"
        }, 
        "location": {
            "contact": {
                "last_name": "Johnson"
            }, 
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093"
                }, 
                "name": "University of California, San Diego"
            }, 
            "investigator": {
                "last_name": "Christina Chambers, PhD, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Stelara\u00ae Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project", 
        "other_outcome": [
            {
                "description": "Rate of spontaneous abortions", 
                "measure": "Spontaneous abortions", 
                "safety_issue": "Yes", 
                "time_frame": "From 3 months prior to the first day of the last menstrual period until the day of delivery"
            }, 
            {
                "description": "Pre- and post-natal fetal and infant growth, small for gestational age, and preterm delivery", 
                "measure": "Infant follow-up, growth", 
                "safety_issue": "Yes", 
                "time_frame": "Birth to one year of age"
            }, 
            {
                "description": "Rate of stillbirth", 
                "measure": "Stillbirths", 
                "safety_issue": "Yes", 
                "time_frame": "From 3 months prior to the first day of the last menstrual period until the day of delivery"
            }, 
            {
                "description": "Health and development including effects to the immune system development.", 
                "measure": "Infant follow-up, Immune system delvelopement", 
                "safety_issue": "Yes", 
                "time_frame": "Birth to 1 year of age"
            }, 
            {
                "description": "Rate of preterm delivery", 
                "measure": "Preterm delivery", 
                "safety_issue": "Yes", 
                "time_frame": "Birth"
            }
        ], 
        "overall_contact": {
            "email": "d4johnson@ucsd.edu", 
            "last_name": "Diana Johnson, MS", 
            "phone": "877-311-8972"
        }, 
        "overall_contact_backup": {
            "email": "jclopez@ucsd.edu", 
            "last_name": "Janina Jimenez, MA", 
            "phone": "877-311-8972"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Diego", 
            "last_name": "Christina Chambers, PhD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to evaluate the effect of certain medications when used in the first trimester of pregnancy with respect to major structural birth defects.", 
            "measure": "Major structural malformations", 
            "safety_issue": "Yes", 
            "time_frame": "From 3 months prior to the first day of the last menstrual period and up to one year of age"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103361"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Diego", 
            "investigator_full_name": "Christina Chambers", 
            "investigator_title": "Professor, Co-Director Center for Promotion of Maternal Health and Infant Development", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "One secondary objective of the study is to evaluate the effects of certain medications when used in the first trimester of pregnancy with respect to potential minor malformations.", 
            "measure": "Minor Congenital Structural Malformations", 
            "safety_issue": "Yes", 
            "time_frame": "At dysmorphological exam which will occur at one time point between birth and one year of age"
        }, 
        "source": "University of California, San Diego", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Organization of Teratology Information Specialists", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Janssen Biotech, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of California, San Diego", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case-Only", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Years", 
        "verification_date": "March 2014"
    }
}